Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The O-polysaccharide (O-antigen) of Salmonella Enteritidis is the distal, repeating carbohydrate component of the lipopolysaccharide (LPS) located on the bacterial outer membrane (NIH, 2024). It is composed of a trisaccharide backbone consisting of mannose, rhamnose, and galactose, with a unique alpha-3,6-tyvelose side chain that defines the O:9 serogroup specificity (NIH, 2024; ASM, 2026). This molecule plays a vital role in bacterial pathogenesis by protecting the organism from complement-mediated lysis and facilitating survival within host macrophages and the environment (ResearchGate, 2024; ASM, 2026). As a primary target of the host immune response, the O-antigen is the focus of various vaccine development efforts, including glycoconjugate vaccines and live attenuated strains (PLOS, 2024; Frontiers, 2024). These vaccines aim to elicit high-titer, functional antibodies that enhance bacterial clearance through opsonization and bactericidal activity (Scilit, 2024; NIH, 2024).
Induction of serovar-specific antibodies (IgG, IgM) that promote opsonophagocytosis and complement-mediated killing of the bacteria.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Salmonella Enteritidis O-polysaccharide antigen (SE OAg).